Format

Send to

Choose Destination
Diabetes Res Clin Pract. 2005 Jun;68(3):202-6. Epub 2004 Dec 8.

Influence of exogenous insulin on C-peptide levels in subjects with type 2 diabetes.

Author information

1
Department of Endocrinology, Hospital Sant Pau, UAB, Sant Antonio Ma Claret, 167, 08025 Barcelona, Spain.

Abstract

AIM:

The aim of this study was to determine whether the influence of insulin therapy on fasting and stimulated C-peptide levels in type 2 diabetic subjects is due to plasma glucose reduction or a direct effect of exogenous insulin.

METHODS:

Plasma glucose and serum C-peptide levels were determined before and after IV injection of 1mg glucagon on three separate days in 21 type 2 diabetic subjects. Day 1: without pharmacological treatment and fasting plasma glucose > 11.1 mmol/L; day 2: fasting plasma glucose 4.4-7.8 mmol/L, 1h after withdrawing intravenous regular insulin infusion; day 3: fasting plasma glucose 4.4-7.8 mmol/L with bed-time NPH insulin.

RESULTS:

Fasting and glucagon stimulated C-peptide levels were higher on day 1 than days 2 and 3. Fasting, but not stimulated C-peptide levels, were lower on day 3 than day 2. These differences were not appeared when the percentage of C-peptide increment or the C-peptide/glucose ratio were compared in the three days.

CONCLUSIONS:

Blood glucose reduction instead of exogenous insulin is responsible for the C-peptide decrease during insulin therapy in type 2 diabetic subjects.

PMID:
15936461
DOI:
10.1016/j.diabres.2004.10.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center